Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Status:
Withdrawn
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the toxicity and pharmacokinetics (PK) of 2-weekly and
3-weekly docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). Also, a
mechanism-based population pharmacokinetics/pharmacodynamics (PK/PD) model will be developed
to provide a better understanding of the complex relationships between the drug exposure and
toxicity profiles of docetaxel in mHSPC.